# JSKN003

Source: https://onco.cc/drugs/jskn003/  
OnCo record `jskn003` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JSKN003 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.

## Summary

JSKN003 is an investigational agent whose form is not stated in the registry developed by Jiangsu Alphamab Biopharmaceuticals and Shanghai JMT-Bio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: JSKN003 should be administered intravenously on the first day of each 3-week cycle. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06079983 (JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects) and NCT06846437 (JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer. The largest, NCT05744427, plans to enrol 725 participants with primary completion was scheduled for 2026-07-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of JSKN003: https://clinicaltrials.gov/search?intr=JSKN003

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- companies: [Alphamab Oncology](https://onco.cc/companies/alphamab/), [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- trials: [JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Iri](https://onco.cc/trials/nct07384377/), [JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer](https://onco.cc/trials/nct06846437/), [JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects](https://onco.cc/trials/nct06079983/), [Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct05744427/)

---
JSON: https://onco.cc/api/v1/entities/jskn003.json